• Patent Approval for GPCR Biosensors
    Pascal Neuville

News & Views

Patent Approval for GPCR Biosensors

Feb 26 2020

French biopharma Domain Therapeutics, developers of drug candidates targeting G Protein-Coupled Receptors (GPCR) in neurology, oncology and rare diseases, has been granted a patent in the US and in Europe, covering a novel family of biosensors that monitor biomolecule localisation and trafficking in cells.
 
The patent, was initially filed by Prof. Michel Bouvier and his team and is part of the technology licensed to Domain Therapeutics by the Universities of Montreal and McGill, Canada. The biosensors are designed to profile G Proteins, including G12 and G13, Beta-arrestins, second messengers and receptor trafficking.
 
“This granted patent illustrates our strategy to stay at the forefront of innovation in technologies for challenging GPCRs. It will help the company address unmet medical needs with drugs acting through brand new mechanisms of action,” said Pascal Neuville, CEO, Domain Therapeutics. “In collaboration with Prof. Michel Bouvier, we have already taken advantage of this unique technology to launch a chaperone program targeting a mutated GPCR with impaired trafficking.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events